Menu

Provider Resources

Surgeons at Mercy Medical Center in Cedar Rapids Preserve More Breast Tissue and Reduce the Need for Additional Surgery by 75% for Breast Cancer Patients with Targeted Excision Using MarginProbe®

FDA approved device enables surgeons to preserve more breast tissue while reducing the need for additional surgery according to medical study.
Learn More

According to a New Clinical Study MarginProbe® Reduces Re-Excision Rate by Half Following Lumpectomies; For DCIS, by Over 60%

MarginProbe provides breast cancer surgeons with real-time information during lumpectomies to help decide whether additional tissue should be excised.
Learn More

Surgeon Spotlight: Dr. Jeffrey Falk – Early Study Data Supports the Value of MarginProbe® in Getting All the Cancer in the First Lumpectomy Surgery

Dr. Jeffrey Falk is a surgical oncologist focusing primarily on breast cancer since starting his practice in 2001. He performs 200-350 breast cancer surgeries annually and has a special interest in research and clinical trials for breast cancer treatments.
Learn More

Emerging Technologies Impacting Cancer Care: How Dune Medical is Helping Surgeons Identify Additional Cancer in the Operating Room

MarginProbe® recognized as a noteworthy medical device for helping reduce positive margins for lumpectomy surgeries by Tim Clay during an interview for News Medical Life Sciences.
Learn More

MarginProbe® Shrinks Positive Margin Rates and Tissue Volume Removed for Both Invasive and DCIS Breast Cancers

Dr. Reid is a firm believer in the success of MarginProbe in improving the results of breast cancer surgery.
Learn More

Physician Insight for Patients: Dr. Vincent Reid – MarginProbe® Shrinks Positive Margin Rates and Tissue Volume Removed for Both Invasive and DCIS Breast Cancers

MarginProbe®  Gives Patients the Best Chance for Only One Lumpectomy Procedure for Both Invasive and DCIS Breast Cancers
Learn More

The Wall Street Journal: If Surgery Got Cancer in One Try

Healthcare Reporter Lucette Lagnado profiles MarginProbe® in The Wall Street Journal featuring Dr. Freya Schnabel, Dr. Alice Police, Dr. Vincent Reid, Dune Medical CEO Lori Chmura and more.
Learn More

Connect with the Dune Medical Team at Miami Breast 2017

For more than three decades, the annual Miami Breast Cancer Conference (MBCC) has brought together…

Learn More

The American Society of Breast Surgeons Annual Meeting 2017

Collectively improving the standard of breast cancer treatment at ASBrS 2017 About the American Society…

Learn More

How Hard Is It To Use MarginProbe®?

Dr. Beth-Ann Lesnikoski, MD, explains the ease in using MarginProbe.
Learn More

How Does MarginProbe® Work?

Dr. Stephanie Akbari, MD, explains how MarginProbe works.
Learn More

How Has MarginProbe® Helped Your Practice?

Dr. Charles Elboim, MD, explains how MarginProbe has helped his practice.
Learn More

How Does MarginProbe® Help Surgeons?

Dr. Charles Elboim, MD, discusses how MarginProbe helps surgeons ensure clean margins while in the operating room.
Learn More

How Confident Are You In MarginProbe®?

Dr. Charles Elboim, MD, expresses his confidence in MarginProbe.
Learn More

Does MarginProbe® Add Time to The Operation?

Surgeons may wonder if using MarginProbe adds time in the operating room during a lumpectomy.
Learn More

Dune Medical Expands Device Portfolio with the Addition of a Reposable Version of MarginProbe®

With sustainability in mind, Dune designed a reposable version of MarginProbe. The new reposable MarginProbe has a reusable cable and handle and a single-use attachable probe. The new probe has the potential to reduce waste burden of MarginProbe up to 50%.
Learn More

Dune Medical’s One-Year Anniversary in Atlanta: Expanding Awareness and Portfolio in the Southeast

It’s been one year since our relocation to Atlanta in August 2017. We have been incredibly busy these past 12 months, and here are some of the highlights!
Learn More

Radio-Frequency Spectroscopy Platform Development Enters Feasibility Testing Phase Supported by Prestigious Horizon 2020 Grant

Capitalizing on the European Union Horizon 2020 research and innovation program, Dune Medical has completed the first phase in the development of its percutaneous soft tissue biopsy device.
Learn More

Dune Medical teams up with Margie’s Army and AreYouDense advocacy to give women with dense breasts access to an earlier diagnosis of their breast cancer

Breast density is one of the most common reasons for failure of mammography to detect cancer and presents unique challenges for breast cancer patients and providers. Despite being a well-established independent risk factor for breast cancer(1), 95% of women do not know their breast density.
Learn More
×
Search